A Southern Highlands man is offering himself up for research into COVID-19 treatment.
Cade Turland described himself as "a data set just sitting here".
Mr Turland, 32, who was case number 110 in Australia is now fully recovered from the virus, but he is well aware that his plasma could be helpful in research.
"I fit the healthy profile," he said.
"I've recovered from the virus, I don't smoke or use drugs and I don't drink excessively."
- Battle for Berrima slams Hume Coal explainer report to the Independent Planning Commission
- Wingecarribee Council prompts neighbours, applicant to meet to address development application concerns
- Wingecarribee Shire Council legal costs pass $90,000 for a month
- Hume Coal rejects 'tired and inaccurate information' from Battle for Berrima
- Southern Highland News introduces Business Hour to help local businesses on the Road to Recovery
- Vale Gina Fallon: Golden Oldies founder loses her battle with cancer
His comments follow news that the plasma of Tasmanians who have fully recovered from COVID-19 could help boost the immunity of patients still battling the disease.
Mr Turland said that he understood that at the moment the key focus was on lowering transmission.
"My blood may not necessarily help, but it could be relevant in treatment if a person is at a certain stage of the virus," he said.
"My blood could be relevant for treatment of certain things and I will make myself available if they want to study it."
Mr Turland said a Melbourne-based research company the Commonwealth Serum Labratory (CSL) Behring has indicated interest in his offer.
CSL Behring is described on its website as a key part of the effort to find a treatment for COVID-19, looking at the use of antibody-rich plasma from those who have recovered from the novel coronavirus to treat patients who are suffering from the illness has emerged as a hopeful potential therapy.
It is developing an anti-SARS-CoV-2 plasma product for the Australian market with the potential to treat people with serious complications of COVID-19, particularly those whose illness is progressing towards the need for ventilation.
The investigational product, to be known as COVID-19 Immunoglobulin, is under development at the company's advanced manufacturing facility located in Broadmeadows, Victoria.
Southern Highland News has contacted CSL for a comment.